RCT of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine

Randomized phase II study of TJ-3020 in patients with unresectable advanced or recurrent pancreatic cancer receiving nab-Paclitaxel plus Gemcitabine

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs041190040

Enrollment

Registered

2019-06-10

Start date

2017-12-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pncreatic cancer Pancreatic cancer

Interventions

TJ-3020

Wisconsin Ginseng, Herbal medicine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable or relapse pancreatic cancer

Exclusion criteria

Exclusion criteria: Herbal medicine Allergies

Design outcomes

Primary

Measure	Time frame
Assessment of fatigue and Malaise	—

Secondary

Measure	Time frame
Assessment of QOL, Assesment of pain, Relative dose intensity	—

Contacts

Public ContactHideki Takami

Nagoya University Graduate School of Medicine

takamihideki@med.nagoya-u.ac.jp+81-52-744-2249

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026